Several other equities analysts also recently issued reports on BABY. Zacks Investment Research downgraded shares of Natus Medical from a buy rating to a hold rating in a report on Wednesday, September 28th. Raymond James Financial Inc. upgraded shares of Natus Medical from a market perform rating to an outperform rating and set a $46.00 target price for the company in a research report on Tuesday, September 13th.
Natus Medical (NASDAQ:BABY) traded up 1.26% during midday trading on Tuesday, reaching $40.19. 89,064 shares of the company’s stock traded hands. The firm’s 50-day moving average is $40.46 and its 200-day moving average is $36.83. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 34.65 and a beta of 0.78. Natus Medical has a 1-year low of $29.54 and a 1-year high of $51.05.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.03. The business had revenue of $96 million for the quarter, compared to the consensus estimate of $92.71 million. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The company’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $0.34 earnings per share. Analysts forecast that Natus Medical will post $1.58 earnings per share for the current year.
In other Natus Medical news, insider James B. Hawkins bought 10,000 shares of Natus Medical stock in a transaction dated Wednesday, September 28th. The stock was acquired at an average cost of $38.48 per share, for a total transaction of $384,800.00. Following the completion of the transaction, the insider now directly owns 459,725 shares of the company’s stock, valued at $17,690,218. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.80% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the stock. Bayesian Capital Management LP purchased a new stake in Natus Medical during the first quarter valued at about $276,000. Invictus RG purchased a new stake in Natus Medical during the first quarter valued at about $148,000. Kennedy Capital Management Inc. boosted its stake in Natus Medical by 88.4% in the first quarter. Kennedy Capital Management Inc. now owns 202,553 shares of the company’s stock valued at $7,784,000 after buying an additional 95,022 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Natus Medical by 6.2% in the first quarter. Lazard Asset Management LLC now owns 135,758 shares of the company’s stock valued at $5,217,000 after buying an additional 7,951 shares during the last quarter. Finally, State Street Corp boosted its stake in Natus Medical by 2.2% in the first quarter. State Street Corp now owns 674,379 shares of the company’s stock valued at $25,914,000 after buying an additional 14,617 shares during the last quarter. Institutional investors and hedge funds own 87.92% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.